Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
· prnewswire.com · popularity 20/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
A post hoc analysis of adults with MASH and liver scarring with a BMI below 27 kg/m² found that measures of liver injury, fibrosis, and disease activity improved at week 72 among participants receiving semaglutide 2.4 mg once weekly injection versus placebo Non-invasive fibrosis...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 4.